Acute coronary syndrome
270 results
191 - 270
Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
Concomitant use of clopidogrel and a PPI may increase risk of adverse CHD outcomes- Flu vaccine reduces risk of adverse CV events in high-risk patients
- Faster discharge but more downstream testing with use of CCTA in ED
- Traditional approach to pretest probability of heart disease overestimates risk
- Pioglitazone does not increase cardiovascular events (PROactive)
- 6-month clopidogrel better than 24 after stent placement (PRODIGY)
- Little if any benefit to early invasive strategy for stable angina and at least moderate reversible ischemia (ISCHEMIA trial)
- High-sensitivity troponin safely reduces admissions and duration of stay in the emergency department
- Less is more when it comes to blood transfusions
Exercise stress test - Antithrombotic agents in primary health care
- Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
- Similar number of cardiovascular events and reduced bleeding with abbreviated dual antiplatelet therapy after PCI
- In patients with vascular disease, treating sleep apnea does not reduce the risk of cardiovascular events
- Lipid lowering is beneficial for secondary prevention but not primary prevention in patients 75 years and older
- Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis
- Interpretation of adult ECG
- COVID-19 and other coronavirus infections
- Clarithromycin associated with cardiovascular events
- Increased readmissions and adverse events with intensification of antihypertensive regimen on hospital discharge
- Promoting patient utilisation of cardiac rehabilitation
- Small reduction in CV outcome after ischemic stroke with lower LDL target, but also harms; no change in all-cause mortality
- Hyperbaric oxygen therapy (HBOT)
- No reduction in postdischarge medication errors after pharmacist-led intervention
- Antiplatelet agents for chronic kidney disease
- Acute abdomen in the adult
- Acute heart failure and pulmonary oedema
- AABB recommends restrictive transfusion strategy for hospitalized patients
- Ipratropium associated with increase risk of CV events
- Taking furosemide on day of surgery does not increase intraop hypotension
- SBP of 120 instead of 140 in adults 75 years or older = significant benefits and some harms (SPRINT)
- Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
- Interpreting BNP in patients with a history of HF
- SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
- Single nondetectable high-sensitivity troponin result rules out AMI
- Sotagliflozin reduces hospitalizations and urgent visits in patients with T2DM and recent HF hospitalization (SOLOIST-WHF)
- Restrictive transfusion strategies are appropriate for most critically ill patients with varying levels of evidence
- Syncope: causes and investigations
- Clinical decision rules for evaluating adults with chest pain in primary care are limited in number and utility — stay tuned
- Increased postoperative 30-day mortality within 1 year of a cardiovascular event
- Viral hepatitis
- Bariatric surgery is associated with fewer major adverse cardiac events than GLP-1 agonists in obese adults with type 2 diabetes
- Legislative smoking bans for reducing secondhand smoke exposure and smoking prevalence
- Management of acute atrial fibrillation
- Final report from SPRINT: lowering SBP below 120 mm Hg decreases major adverse cardiac events and all-cause mortality
- Indications for and implementation of anticoagulant therapy in atrial fibrillation
- Chronic heart failure
- Risk of stroke after TIA is 2.8% at 1 month and 5.1% at 1 year
- Cardiac biomarkers (BNP and troponin) useful for diagnosis and prognosis of cardiac syncope (BASEL IX)
- Warfarin therapy
- In high-risk older patients with atrial fibrillation, rhythm control reduces cardiovascular death and stroke, but at a price
- Higher blood pressure targets for hypertension in older adults
- Treatment of dyslipidaemias
- Angiotensin II increases BP in vasodilatory shock resistant to high-dose vasopressors
- Apixaban reduces stroke and embolism more than aspirin in A fib
- Identification of illegal drug overdose and diagnosis of illegal drug poisoning
- Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
- Overview of new ACC/AHA lipid guidelines: here we go again
- Comprehensive treatment and follow-up of type 2 diabetes
- Heart valve operation: patient follow-up and complications
- For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
- Legislative smoking bans for reducing harms from secondhand smoke exposure, smoking prevalence and tobacco consumption: Cochrane systematic review
- Behavioural activation therapy for depression in adults with non‐communicable diseases
- Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease
- Supraventricular tachycardia (SVT)
- Prehospital emergency care
- Transfusion thresholds for guiding red blood cell transfusion
- Atherectomy for peripheral arterial disease
- Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women
- Oral antidiabetic drugs and GLP-1 analogues
- Prevention of depression in adults with long‐term physical conditions
- Palliative treatment